Supported by an educational grant from Sunovion Pharmaceuticals, Inc.
Adults with chronic obstructive pulmonary disease (COPD) are more likely to be unable to work and have diminished activities of daily living. They also have increased comorbid conditions, difficulty walking or climbing stairs, or need special equipment to manage health problems compared with adults without COPD. Moreover, COPD is the 3rd most common cause of death in the US just behind cancer and heart disease. Despite significant local and national efforts to reduce the burden of COPD, recent data from the Nationwide Inpatient Sample (NIS) and Nationwide Emergency Department Sample (NEDS) has revealed that total hospitalizations and ED visits for COPD over the past decade have continued to increase. However, COPD is listed as one of the conditions in which hospitalizations are preventable to some degree. For patients with COPD, arthritis, depression, congestive heart failure, diabetes, coronary heart disease, and asthma are more common among patients with COPD than those without COPD.
This educational initiative has been designed for pulmonologists and internal medicine physicians involved in the care of patients with COPD.
Upon completion of this educational activity, participants should be able to:
Describe a long-term management plan that improves disease monitoring, risk assessment, and exacerbation prevention in patients with COPD
Review the efficacy and safety of newer bronchodilator therapies and their combinations for patients with COPD
Select COPD medications and their devices based on the individualized needs of patients with COPD
Conflict Of Interest Disclosure Policy
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education, Inc. is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity under the Faculty heading below.
Brian W. Carlin, MD, FCCP, MAACVPR, FAARC Sleep Medicine and Lung Health Consultants Senior Staff Physician Pittsburgh Critical Care Associates Pittsburgh, PA
Dr. Carlin discloses the following: Consulting Fees and Speakers’ Bureau: AstraZeneca, GlaxoSmithKline, Monaghan Medical, Nonin, Philips Respironics, Sunovion Pharmaceuticals, Inc.
Sidney S. Braman, MD, FACP, FCCP Professor of Medicine Pulmonary, Critical Care, and Sleep Medicine Icahn School of Medicine New York, NY
Dr. Braman discloses the following: Consultant: AstraZeneca, Covidien, Sunovion Pharmaceuticals, Inc. Speakers’ Bureau: Genentech
Accredited Provider Disclosure
The following planner and manager, Patima Tanapat, PhD, hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
AMA PRA Category 1 Credit(s)TM
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education, Inc., designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Inc., and Sunovion Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Sunovion Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
There are no fees for participating and receiving CME credit for this activity. During the period of February 1, 2018 through February 1, 2019, participants must:
Read the learning objectives and faculty disclosures
Complete the pre-test
Study the educational activity
Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or email@example.com.